Uncovering the Power of AI-Driven Immunotherapy at BTIG’s Virtual Biotech Conference!

AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company committed to advancing precision medicine for neurodegenerative diseases, today announced that their team will participate in a Fireside chat and one-on-one investor meetings during the BTIG Virtual Biotechnology Conference 2023 on August 7-8. This will provide an opportunity for attendees to gain insights into the company’s research and development efforts and to network with industry professionals.

Join us for a unique and exciting Fireside chat with Dr. Andrea Pfeifer, CEO of AC Immune SA, as she delves into how the company is weaving together clinical stage active immunotherapies to create a powerful solution to Alzheimer’s and other neurodegenerative diseases. Discover how they plan to tackle and ultimately prevent these heartbreaking disorders.

Join us on August 8th for the exciting Fireside Chat with AC Immune’s Management! Listen in to hear the CEO and team discuss their strategies and plans for the future, as well as respond to any questions or comments from investors.

This special event will take place at 9:30AM EDT/3:30PM CEST and a replay will be available through the BTIG Virtual Biotechnology Conference platform. Don’t miss this unique chance to gain insights from one of the leaders in innovative biotechnologies!

About AC Immune SA

AC Immune, a pioneering clinical-stage biopharmaceutical company, is revolutionizing the way neurologic diseases, such as Alzheimer’s, Parkinson’s and NeuroOrphan indications driven by misfolded proteins, are diagnosed and treated.

At the heart of this effort is the company’s two validated technology platforms, SupraAntigen® and Morphomer®, which is fueling AC Immune’s broad and diverse portfolio of first- and best-in-class therapeutic and diagnostic programs.

With five of these programs now in Phase 2 clinical trials and one in Phase 3, AC Immune is at the forefront of the precision medicine revolution. Furthermore, the company’s key partnerships with some of the biggest players in the industry—roche group’s Genentech, Eli Lilly and more—have led to substantial, non-dilutive funding for their projects and the potential for over $3 billion in milestone payments.

Leave a Comment